Skip to main content

Advertisement

Table 3 Characteristics of neuroprotectant use

From: Current management of intracerebral haemorrhage in China: a national, multi-centre, hospital register study

Neuroprotectant n (%*)
Edaravone 95 (8.4)
Ganglioside GM1 29 (2.6)
Cattle encephalon glycoside and ignotin 112 (9.9)
Cinepazide 56 (5.0)
Citicholine 334 (29.6)
Other 198 (17.5)
Unspecified 321 (28.4)
  1. *As a proportion of all patients on any neuroprotectant therapy (n = 1130); groups are not mutually exclusive as 1 patient may be on more than 1 neuroprotectant
  2. Use of agents including deproteinised calf blood extracts, adenosine triphosphate, cerebroprotein extracts, cytidine disodium triphosphate, lysine, piracetam, meclofenoxate, and sodium fructose diphosphate.